Cas:30544-34-4 2,3-Dibromofuran manufacturer & supplier

We serve Chemical Name:2,3-Dibromofuran CAS:30544-34-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,3-Dibromofuran

Chemical Name:2,3-Dibromofuran
CAS.NO:30544-34-4
Synonyms:2,3-dibromofuran;MFCD01074839
Molecular Formula:C4H2Br2O
Molecular Weight:225.86600
HS Code:2932190090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:75-78ºC 75mm
Density:2
Index of Refraction:1.547
PSA:13.14000
Exact Mass:223.84700
LogP:2.80460

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1992 6.1(3) / PGIII
Packing Group:


Contact us for information like 2,3-dibromofuran chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD01074839 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01074839 Use and application,MFCD01074839 technical grade,usp/ep/jp grade.


Related News: There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 2,3-Dibromofuran manufacturer There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. 2,3-Dibromofuran supplier We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� 2,3-Dibromofuran vendor The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 2,3-Dibromofuran factory There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association.